Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

HHS Secretary Alex Azar at the podium. Photo: Chip Somodevilla/Getty Images

Pharmaceutical companies' stocks soared Friday when President Trump released his plan to curb prescription drug costs — and that's a pretty accurate assessment of how big a threat this proposal is.

The bottom line: It would mostly move costs around. There are few new steps in here to try to lower the sticker price of prescription drugs. It does call for increased competition from generics — a push that's already well underway at the Food and Drug Administration — but focuses most of its attention on middlemen.

Some of those goals are contradictory.

  • "We are calling into question, today, the entire structure of using rebates as the method of negotiating discounts," HHS Secretary Alex Azar said during Friday's White House press briefing.
  • But in the meantime, the proposal would give pharmacy benefit managers — the companies that negotiate those rebates — a bigger role in Medicare.

Real change is a long way away. The plan includes few immediate actions, and more calls to either study an issue or for Congress to act — both of which give industry more room to flex its lobbying muscle.

Some ideas may not work: Experts have already questioned whether parts of the plan are feasible — not just politically, but substantively.

  • Trump, for example, wants foreign single-payer systems to start paying more for drugs, saying their low prices mean that U.S. payers end up footing the bill for all the world's research and development.
  • "I don’t think the fact that I pay higher prices than students at movie theaters lowers their price, so I’m not particularly bullish on this idea either. Prices reflect willingness to pay, and with pharmaceuticals, the United States is willing to pay a lot. We’ll pay less when we decide to pay less," American Enterprise Institute's Ben Ippolito told Axios' Caitlin Owens.

Even the small things are hard: One seemingly minor proposal from Trump's proposal helps explain how many steps are involved here, and how that complexity can lead to stasis.

  • The proposal: "Call on the FDA to evaluate the inclusion of list prices in direct-to-consumer advertising."
  • Breaking it down: Drugs' list prices absolutely matter, especially to the uninsured and people with high deductibles, who often have to pay at least some part of the list price before their coverage kicks in.
  • But most patients don't pay the list price. Their prices have been discounted by some combination of wholesalers, PBMs, insurers, employers and Medicaid rebates. And then the consumers themselves only pay some portion of that discounted price.
  • So, disclosing the list price — the highest relevant number — would give many consumers an artificially inflated understanding of how much they would have to pay. And, because there's so much variance in the prices for each payer, it's hard to find another metric that would give consumers a better idea of what they're in for.

The big question: I asked Nick Bagley and Jonathan Adler — two law professors who are often on opposite sides of health care legal issues — whether there could be any First Amendment problems with requiring drug makers to disclose their list prices. Both said the government would be on solid ground.

  • Yes, but: With so many technical and policy questions, you can see how even this relatively simple proposal could end up not making it across the finish line.
The system is rocket science. It's unbelievably complex.
— Alex Azar, HHS secretary

Go deeper

Hope King, author of Closer
Updated 51 mins ago - Economy & Business

Peloton pumps its brakes

Data: FactSet; Chart: Axios Visuals

Peloton’s popularity is falling as swiftly as it shot up.

Why it matters: Not all pandemic habits stick around. Peloton's trajectory over the past two years exemplifies how challenging it's been for companies to gauge shifts in consumer demand — particularly in sectors heavily altered by the pandemic.

Mitch McConnell's remarks on Black voters raise ire

Senate Minority Leader Mitch McConnell during a Capitol Hill news conference earlier this year. Photo: Anna Moneymaker/Getty Images

Senate Minority Leader Mitch McConnell (R-Ky.) has been widely criticized for comments he made this week about Black American voters.

Driving the news: When asked by a reporter Wednesday about concerns among voters of color, McConnell said "the concern is misplaced, because if you look at the statistics, Black American voters are voting in just as high a percentage as Americans."

Updated 2 hours ago - Politics & Policy

Scoop: Trump’s friends worry legal pick for N.Y. case lacks experience

Photo illustration: Sarah Grillo/Axios. Photo: Brandon Bell/Getty Images

Close associates and advisers to Donald Trump tell Axios they're concerned by his decision to use a relatively inexperienced New Jersey attorney, Alina Habba, in his high-stakes legal fight against New York Attorney General Letitia James.

Why it matters: A former president typically has access to the country's most prestigious experts, including lawyers. Trump has turned to the former general counsel for a parking garage company, who works from a small law office near his Bedminster, N.J., country club.